Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C41H47Cl2NO6 |
| Molecular Weight | 720.721 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@H](OC(=O)COC(=O)CCCC3=CC=C(C=C3)N(CCCl)CCCl)[C@@]1(C)CC[C@]4([H])C5=C(CC[C@@]24[H])C=C(OC(=O)C6=CC=CC=C6)C=C5
InChI
InChIKey=IFJUINDAXYAPTO-UUBSBJJBSA-N
InChI=1S/C41H47Cl2NO6/c1-41-21-20-34-33-17-15-32(49-40(47)29-7-3-2-4-8-29)26-30(33)12-16-35(34)36(41)18-19-37(41)50-39(46)27-48-38(45)9-5-6-28-10-13-31(14-11-28)44(24-22-42)25-23-43/h2-4,7-8,10-11,13-15,17,26,34-37H,5-6,9,12,16,18-25,27H2,1H3/t34-,35-,36+,37+,41+/m1/s1
Atrimustine [bestrabucil, busramustine, KM 2210, kregan], a conjugate of estradiol and chlorambucil, is a DNA antagonist that was developed by Kureha Corporation (Japan). Atrimustine is an antineoplastic drug that was used for the treatment of breast cancer, non-Hodgkin's lymphoma, as well as Graft-versus-host disease. Side effects of atrimustine in clinical trials included vaginal bleeding and gynecomastia. Atrimustine reached preregistration in Japan for the treatment of cancer, however, its development has been discontinued.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Atrimustine is considered to be useful for the treatment of advanced and recurrent breast cancer when administered at a dose level of 200 mg per day for more than 4 weeks. https://www.ncbi.nlm.nih.gov/pubmed/8135468
Thirteen patients with hematological neoplasms were treated with Atrimustine (100 mg/day po, total dose 700-9,900 mg).
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C574
Created by
admin on Sat Dec 16 18:05:27 GMT 2023 , Edited by admin on Sat Dec 16 18:05:27 GMT 2023
|
||
|
NCI_THESAURUS |
C697
Created by
admin on Sat Dec 16 18:05:27 GMT 2023 , Edited by admin on Sat Dec 16 18:05:27 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Atrimustine
Created by
admin on Sat Dec 16 18:05:27 GMT 2023 , Edited by admin on Sat Dec 16 18:05:27 GMT 2023
|
PRIMARY | |||
|
100000086637
Created by
admin on Sat Dec 16 18:05:27 GMT 2023 , Edited by admin on Sat Dec 16 18:05:27 GMT 2023
|
PRIMARY | |||
|
DTXSID501046416
Created by
admin on Sat Dec 16 18:05:27 GMT 2023 , Edited by admin on Sat Dec 16 18:05:27 GMT 2023
|
PRIMARY | |||
|
SUB05605MIG
Created by
admin on Sat Dec 16 18:05:27 GMT 2023 , Edited by admin on Sat Dec 16 18:05:27 GMT 2023
|
PRIMARY | |||
|
C1348
Created by
admin on Sat Dec 16 18:05:27 GMT 2023 , Edited by admin on Sat Dec 16 18:05:27 GMT 2023
|
PRIMARY | |||
|
CHEMBL2106381
Created by
admin on Sat Dec 16 18:05:27 GMT 2023 , Edited by admin on Sat Dec 16 18:05:27 GMT 2023
|
PRIMARY | |||
|
XC0K09B7K4
Created by
admin on Sat Dec 16 18:05:27 GMT 2023 , Edited by admin on Sat Dec 16 18:05:27 GMT 2023
|
PRIMARY | |||
|
6407
Created by
admin on Sat Dec 16 18:05:27 GMT 2023 , Edited by admin on Sat Dec 16 18:05:27 GMT 2023
|
PRIMARY | |||
|
6917688
Created by
admin on Sat Dec 16 18:05:27 GMT 2023 , Edited by admin on Sat Dec 16 18:05:27 GMT 2023
|
PRIMARY | |||
|
75219-46-4
Created by
admin on Sat Dec 16 18:05:27 GMT 2023 , Edited by admin on Sat Dec 16 18:05:27 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
